FDA Approves Daliresp Dosage as First-line Therapy for Severe COPD
AstraZeneca’s Daliresp (roflumilast) is now approved at 250 micrograms (mcg) for the first four weeks followed by 500 mcg thereafter to treat patients with chronic obstructive pulmonary disease (COPD). This approval by the U.S. Food and Drug Administration (FDA) will help reduce the rate of discontinuation previously reported in patients…